Indeed, Cherney et al17 reported that urinary total angiotensinogen excretion, which represents local RAS activity in the kidney,18 19 significantly increased owing to treatment with SGLT2 inhibitors in patients with type 1 diabetes mellitus. Here, SLC5A2 is linked to type 1 diabetes mellitus.